Pending — not yet graded
“Estimates Pine Labs' FY28 UPI MDR revenue at Rs 1.55 billion. The discounted value of this revenue stream could add Rs 51.5 billion to the company's valuation, or about Rs 43 per share. Consequently, Emkay has raised its target price for Pine Labs to Rs 230 from Rs 190.”
Pine LabsBullishCalled 16 Sep 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.
Read the original articleSee Emkay Global Financial Services Analysis’s full track record